Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 263Breast 157Thoracic 93Gynecologic 40Head & Neck 35Genitourinary 24Tumor-Agnostic 21Dermatologic 20Sarcoma 14Other solid neoplasm 11Lymphoid 8CNS 5Other neoplasm 4Plasma cell 3Other hematologic neoplasm 3Myeloid 1Endocrine 1Classical hematology 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Albumin-Bound Paclitaxel × Endocrine × Clear all
NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
50 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡